Cost of pharmacological care of the elderly: Implications for healthcare resources

Drugs and Aging

Volumn 20, Issue 4, 2003, Pages 253-261

  O'Neill, Ciaran ^a   Hughes, Carmel M ^b   Jamison, James ^b   Schweizer, Anna ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISABILITY; DRUG COST; EDUCATION; ELDERLY CARE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; METHODOLOGY; OUTCOMES RESEARCH; PATIENT COUNSELING; POLITICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH PLANNING; HEALTH SERVICES FOR THE AGED; HUMANS; PHARMACEUTICAL PREPARATIONS; POPULATION DYNAMICS;

EID: 0037251581     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320040-00002     Document Type: Review

References (60)

1. Woloshin S, Schwartz LM, Trammel J, et al. Direct-to-consumer advertisements for prescription drugs: what am Americans being sold? Lancet 2001; 358 (9288): 1141-6
2. Zweifel P, Ferrari M. Is there a Sisyphus syndrome in health care? In: Zweifel P, Frech III HE, editors. Health economics worldwide. Amsterdam: Kluwer, 1992: 3111-330
3. Anderson GF, Hussey PS. Population aging: a comparison among industrialized countries. Health Aff 2000; 19: 191-212
4. United Nations. Demographic Yearbook, Series R. New York: (United Nations publication, Sales No. E/F.98.XIII.1) 1996
5. Metge C, Black C, Peterson S, et al. The population's use of pharmaceuticals. Med Care 1999; 37 (6): JS42-59
6. Mueller C, Schur C, O'Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health 1997; 87 (10): 1626-9
7. Hoffman C, Rice D, Sung HY. Persons with chronic conditions, their prevalence and costs. JAMA 1996; 276 (18): 1473-9
8. Skoll SL, August RL, Johnson GE. Drug prescribing for the elderly in Saskatchewan during 1976. CMAJ 1979; 121: 1074-81
9. Hale WE, May FE, Marks RG, et al. Drug use in an ambulatory elderly population: a five year update. Drug Intell Clin Pharm 1987; 21: 530-5
10. Nolan L, O'Malley K. Patients, prescribing and benzodiazepines. Eur J Clin Pharmacol 1988; 35: 225-9
11. Kobayashi Y. Health care expenditures for the elderly and reforms in the health care system in Japan. Health Policy 1994; 29: 197-208
12. Lillard LA, Rogowski J, Kington R. Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population. Med Care 1999; 37: 926-36
13. Long SH. Prescription drugs and the elderly: issues and options. Health Aff 1994; 13: 157-74
14. Freund DA, Willison D, Reeher G, et al. Outpatient pharmaceuticals and the elderly: policies in seven nations. Health Aff 2000; 19: 259-66
15. Thomas CP, Ritter G, Wallack SS. Growth in prescription drug spending among insured elders. Health Aff 2001; 20: 265-77
16. Heffler S, Levit K, Smith S, et al. Health spending growth up in 1999; faster growth expected in the future. Health Aff 2001; 20: 193-203
17. Mehl B, Santell J. Projecting future drug expenditures-2001. Am J Health Syst Pharm 2001; 58: 1251-33
18. Anderson GM, Kerluke KJ, Pulcins IR, et al. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Inquiry 1993; 30: 199-207
19. Bodenheimer TS. Affordable prescriptions for the elderly JAMA 2001; 286: 1762-3
20. Pitkala KH, Valvanne J, Kulp S, et al. Secular trends in self-reported functioning, need for assistance and attitudes towards life: 10-year differences of three year older cohorts. J Am Geriatr Soc 2001: 49: 596-600
21. Liao Y, McGee DL, Cao G, et al. Quality of the last year of life of older adults: 1986 vs 1993. JAMA 2000; 283: 512-8
22. Manton KG, Corder LS, Stallard E. Monitoring changes in the health of the US elderly population: correlates with biomedical research and clinical innovations. FASEB J 1997; 11: 923-30
23. Singer BH, Manton KG. The effects of heath changes on projections of health service needs for the elderly population of the United States. Proc Natl Acad Sci U S A 1998; 95: 15618-22
24. Worrall A, Rea JN, Ben-Shlomo Y. Counting the cost of social disadvantage in primary care: retrospective analysis of patient data. BMJ 1997; 314: 38-42
25. Malmstrom M, Johansson SE, Sundquist J. A hierarchical analysis of long-term illness and mortality in socially deprived areas. Soc Sci Med 2001; 53: 265-75
26. Crimmins EM, Saito Y. Trends in healthy life expectancy in the United States, 1970-1990: gender, racial and educational differences, Soc Sci Med 2001; 52: 1629-41
27. Perls TT, Wood ER. Acute care costs of the oldest old. Arch Intern Med 1996; 156: 754-60
28. Fries JF. Aging, natural death and the compression of morbidity. N Engl J Med 1980; 303: 130-5
29. Berndt ER, Cockburn IM, Cocks DL, et al. Prescription drug prices for the elderly. Mon Labor Rev 1998; 121: 23-34
30. McKercher PL. Pharmaceuticals in Medicare reform. Clin Ther 1997; 19: 1426-32
31. Fairman KA. The effect of new and continuing prescription drug use on cost: a longitudinal analysis of chronic and sea-sonal utilization. Clin Ther 2000; 22: 641-52
32. Abrams WB, Beers MH. Clinical pharmacology in an aging population. Clin pharmacol Ther 1998; 63: 281-4
33. Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by Medicare enrollees: does type of drug coverage matter? Health Aff (Millwood) 2001; 20: 276-87
34. Adams AS, Soumerai SB, Ross-Degnan D. The case for a Medicare drug coverage benefit: a critical review of the empirical evidence. Annu Rev Public Health 2000; 22: 49-61
35. Leibowitz A, Manning WG. Newhouse JP. The demand for prescription drugs as a function of cost sharing. Soc Sci Med 1985; 21: 1063-9
36. Aaronson WE, Zinn JS, Rosko MD. The success and repeal of the Medicare Catastrophic Coverage Act: a paradoxical lesson for health care reform. J Health Polit Policy Law 1994; 19: 753-71
37. AARP Facts. What is AARP? [online]. Available at URL: www.aarp.org. [Accessed 2002 Jul 15]
38. Zweibel NR, Cassel CK, Karrison T. Public attitudes about the use of chronological age as a criterion for allocating health care resources. Gerontologist 1993; 33: 74-80
39. Williams A. Intergenerational equity: an exploration of the 'fair innings' argument. Health Econ 1997; 6: 117-32
40. Shaw AB. Age as a basis for healthcare rationing: support for agist policies. Drugs Aging 1996; 9: 403-5
41. Scharf S, Flamer H, Christophidis N. Age as a basis for healthcare rationing: arguments against agism. Drugs Aging 1996; 9: 399-402
42. Department of Health. National service framework for older people. London: Department of Health, 2001
43. Crystal S, Johnson RW, Harman J, et al. Out-of-pocket health care costs among older Americans. J Gerontol B Psychol Sci Soc Sci 2000; 55B (1): S51-62
44. Steinberg EP, Gutierrez B, Momani A, et al. Beyond survey data: a claims-based analysis of drug use and spending by the elderly. Health Aff 2000; 19: 198-211
45. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991; 325: 1072-7
46. Soumerai SB, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescription drugs under Medicaid: effect on therapy, cost, and equity. N Engl J Med 1987; 317: 550-6
47. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331: 650-5
48. Federman AD, Adams AS, Ross-Degnan D, et al. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA 2001; 286: 1732-9
49. Blustein J. Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Aff 2000; 19: 219-30
50. Rogowski J, Lillard LA, Kington R. The financial burden of prescription drug use among elderly persons. Gerontologist 1997; 37: 475-82
51. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001; 285: 421-9
52. Walley T. Prescription charges: change overdue? BMJ 1998; 317: 487-8
53. Sias JJ, Bennett MS. A reimbursable education service for patients with hepatitis C. J Am Pharm Assoc 2001; 41 (3): 448-53
54. Timmer JW, de Smet PA, Schuling J, et al. Patient education to users of oral hypoglycemic agents: the perspective of Dutch community pharmacists. Pharm World Sci 1999; 21 (5):200-4
55. Crealey GE, McElnay JC, Maguire TA, et al. Costs and effects associated with a community pharmacy-based smoking-cessation programme. Pharmacoeconomics 1998; 14 (3): 323-33
56. Shmucker DL, Vesell ES. Are the elderly under-represented in clinical drug trials? J Clin Pharmacol 1999; 39: 1103-8
57. Lapane KL, Hughes CM. Optimising drug utilisation in long term care. Pharmacoeconomics 2002; 20: 143-52
58. Gorham P. Cost-effectiveness guidelines: the experience of Australian manufacturers. Pharmacoeconomics 1995; 8: 369-73
59. Bernsten C, Bjorkman I, Caramona M, et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven european countries. Drugs Aging 2001; 18 (1): 63-77
60. Carter BL, Malone DC, Valuck RJ, et al. The IMPROVE study: background and study design. Am J Health Syst Pharm 1998; 55: 62-7